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Abstract
Chorioamnionitis refers to inﬂammation of the amniochorionic membrane, and is a signiﬁcant cause of maternal and neonatal morbidity.
Chorioamnionitis most often occurs as a result of ascending infection, and is commonly associated with premature rupture of the mem-
branes. Chorioamnionitis is generally the result of a polymicrobial infection, with Ureaplasma urealyticum, Mycoplasma hominis and Gram-
negative anaerobes being frequent causative organisms. The mainstay of treatment includes antimicrobial agents, antipyretics, expedition
of delivery and supportive care. Further research is required to identify mechanistic pathways and early biomarkers that accurately pre-
dict women at higher risk of adverse maternal and neonatal outcomes, and that can thus lead to the development of additional treat-
ment and prevention strategies.
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Introduction
Chorioamnionitis (or intra-amniotic infection) refers to
inﬂammation of the amniochorionic membrane (both cho-
rion and amnion). It is estimated to be present in approxi-
mately 2–4% of term pregnancies [1], and in approximately
40–70% of women who deliver prematurely [2,3]. Chorio-
amnionitis can be deﬁned both clinically, on the basis of
maternal symptoms including fever, abdominal pain, abnor-
mal vaginal discharge and leukocytosis [4], and histo-
logically, with evidence of inﬂammation and necrosis
throughout the chorionic plate and amnion [5]. Chorioam-
nionitis is associated with signiﬁcant maternal and neonatal
morbidity and mortality. Neonatal morbidities include an
increased risk of neonatal sepsis and pneumonia [6]. Fur-
thermore, chorioamnionitis may result in a fetal inﬂamma-
tory response syndrome, which carries with it increased
risks of periventricular leukomalacia, cerebral palsy [7] and
chronic lung disease [8]. The earlier the degree of prema-
turity, the higher the likelihood of detecting histological
chorioamnionitis. One study found that, of those cases
delivering at 21–24 weeks, 67% demonstrate evidence of
histological infection and inﬂammation, as compared with
22% of those delivering at 33–36 weeks [9]. In addition to
these fetal and neonatal complications, chorioamnionitis can
pose signiﬁcant maternal risks. These include postpartum
haemorrhage, uterine atony, increased risk of caesarean
section, and rarer complications such as septic shock, adult
respiratory distress syndrome and coagulopathies [10].
Caesarean section performed in the presence of intra-amni-
otic infection is associated with an increased risk of mater-
nal blood transfusion, septic pelvic thrombophlebitis, pelvic
abscess formation [11] and surgical site infections [12].
These complications result not only in signiﬁcant maternal
morbidity, but also in increased healthcare costs.
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Aetiology of Chorioamnionitis
Chorioamnionitis occurs most often as a result of ascending
bacteria from the vagina and cervix, and is most commonly
seen as a secondary complication of prolonged rupture of the
membranes [13]. Less common modes of transmission include
haematogenous spread or transmission following an invasive
procedure (i.e. amniocentesis, chorionic villous sampling or
other fetal procedure). Various bacterial, viral and, rarely, fun-
gal agents have been linked to the underlying pathogenesis of
chorioamnionitis and preterm birth (PTB). Some of these
commonly identiﬁed pathogens include Ureaplasma urealyti-
cum, Chlamydia trachomatis, Neisseria gonorrhoea, Mycoplasma
hominis, group B streptococcus and Trichomonas vaginalis
[14,15]. Additional bacteria include Gram-negative anaerobes,
including Gardnerella vaginalis and Bacteroides spp. [16].
Cultured specimens from patients with clinical chorioam-
nionitis most often reveal a polymicrobial infection, with the
majority of women having at least two detectable pathogens.
The frequency of isolation of certain pathogens in chorioam-
nionitis varies with the study and the type of tissue analysed.
The most frequent isolates from placentas of preterm infants
were U. urealyticum (47%) and G. vaginalis (26%) [3]. Similar
microbiological isolates were detected in the amniotic ﬂuid
of women with intra-amniotic infection, with the most com-
mon organisms detected being U. urealyticum (47%), any
Gram-negative anaerobe (38.4%), M. hominis (30.4%), Bactero-
ides bivius (29.5%) and G. vaginalis (24.5%) [16].
Viruses may also play a role in chorioamnionitis. Multiple
viruses, including cytomegalovirus, adenovirus, enterovirus,
respiratory syncytial virus and Epstein–Barr virus, have been
isolated from amniotic ﬂuid [17]. Recently, investigators
demonstrated that placental adenovirus infection was
strongly associated with histological chorioamnionitis (75%
vs. 36%; p 0.026) and PTB (41% vs. 21%; OR 2.6;
95% CI 1.4–5.1; p <0.002) [18]. Although these viruses have
been isolated and implicated in cases of chorioamnionitis,
supportive evidence for viruses, including Epstein–Barr virus
and others, actually causing chorioamnionitis is very limited.
Fungal organisms, including several species of Candida
(Candida albicans, Candida tropicalis and Candida glabrata), have
also been associated with chorioamnionitis [19–21]. These
infections have been reported in women with in vitro fertiliza-
tion pregnancies, in those with retained intrauterine contra-
ceptive devices, following amniocentesis, and in those with
prolonged rupture of membranes [19,22,23]. Only 0.8% of
candidal vaginal infections actually ascend into the uterus,
and even fewer result in acute chorioamnionitis [20]. How-
ever, the complications of intra-amniotic fungal infection can
be severe, with a 75% risk of prematurity being associated
with candidal funisitis [20]. Also, there are increased risks of
mortality in immature/low-birthweight (<1500 g) infants with
congenital systemic candidiasis [24].
Finally, there have been case reports of methicillin-
resistant Staphylococcus aureus causing chorioamnionitis, but
there are no reports at the time of publication of chorioam-
nionitis associated with vancomycin-resistant Enterococcus.
Methicillin-resistant S. aureus and possibly vancomycin-resis-
tant Enterococcus infection should be considered in women
with clinical chorioamnionitis refractory to treatment, as well
as in those with recurrent or prolonged admission to hospi-
tal or who themselves are healthcare workers [25,26].
Organisms such as Mycoplasma are typically low-virulence
organisms, which may explain why women with histological
chorioamnionitis often have no clinical symptoms. Despite
multiple reports documenting the positive culture of bacteria
and/or viruses from women with chorioamnionitis, the pres-
ence of bacteria and their products alone is not sufﬁcient to
induce chorioamnionitis. In addition to the presence of these
bacteria/viruses, the elicited host immune response plays an
integral role in determining outcomes, including clinical cho-
rioamnionitis, PTB and premature preterm rupture of the
membranes (PPROM) [27,28]. Research is ongoing, including
projects such as the Human Microbiome Project. This group
works to further characterize the microbial communities
found in the female genital tract, both in normal pregnancy
and in pathological conditions such as chorioamnionitis (31st
Annual Meeting of the Society for Maternal Fetal Medicine,
Abstract 73) [29].
Risk factors for Chorioamnionitis
Apart from colonization with bacteria and viruses, there are
several risk factors for the development of chorioamnionitis.
As discussed above, prematurity and PPROM are commonly
associated with chorioamnionitis. At term, risk factors
include long duration of labour and rupture of membranes,
and nulliparity [30]. Furthermore, women with pre-labour
rupture of membranes at term who receive multiple digital
vaginal examinations, have a prolonged labour or have meco-
nium-stained liquor are at higher risk of developing chorio-
amnionitis [31].
Diagnosis
Chorioamnionitis can be diagnosed with the use of histologi-
cal or clinical criteria. The clinical diagnosis is based on signs
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and symptoms of local or systemic infection. A common def-
inition includes maternal pyrexia (fever >37.5–38C) and one
of the following: abdominal pain, uterine tenderness, foul vag-
inal discharge, maternal tachycardia (>100 beats/min), fetal
tachycardia (persistent elevation of fetal heart rate >160 -
beats/min) and an elevated maternal white blood cell count
(>15 000 cells/mm3) [4,32,33]. The cut-off for maternal pyr-
exia varies across several studies, but more recent literature
generally quotes a value for deﬁnition purposes of >38.0C,
to exclude the many women with a low-grade fever during
labour unrelated to an infectious process.
Chorioamnionitis can occur histologically, and is staged on
the basis of speciﬁc criteria, with increasing neutrophil inﬁl-
tration and the development of necrosis, amnion basement
membrane thickening and chorionic microabscesses being
seen with increasing disease severity [5] (Fig. 1). In addition,
the fetal inﬂammatory response may progress from chori-
onic/umbilical vasculitis (neutrophil inﬁltration in the
chorionic or umbilical vessels) to necrotizing funisitis (inﬂam-
mation of the connective tissue of the umbilical cord) [5].
The clinical diagnosis of chorioamnionitis, however, is not
always conﬁrmed by histological or microbiological studies.
In one study of 139 pregnancies with clinical ﬁndings of
chorioamnionitis, histological examination of the placenta did
not support the clinical diagnosis in approximately one-third
of cases [34].
Chorioamnionitis, as deﬁned by positive amniotic ﬂuid cul-
tures, is found in 36% of women with PPROM [35]. Although
amniocentesis with culture of the amniotic ﬂuid is ideal for
isolating bacteria, and is the reference standard for the pur-
poses of diagnosis, this test is associated with a delay of at
least 48 h for cultures, with no evidence of predictive value
for potential maternal and neonatal outcomes. There is also
a lack of good-quality trials to demonstrate that this
approach reduces either maternal or neonatal morbidity.
One study investigated the use of amniocentesis, placental
swabs and neonatal skin swabs in the subsequent manage-
ment of chorioamnionitis following delivery. There was a
strong association between positive amniotic cavity culture
results and clinical early-onset sepsis; however, there
remains insufﬁcient evidence to justify the routine perfor-
mance or recommendation of amniocentesis for the pur-
poses of diagnosis [35,36].
The evidence supporting the use of blood cultures for the
diagnosis of chorioamnionitis is also limited. It appears that
the routine use of maternal blood cultures rarely provides
information that justiﬁes a change in clinical management
when patients are treated in accordance with a speciﬁc anti-
biotic protocol [37]. Furthermore, there is no good-quality
evidence to show the beneﬁt of the use of high vaginal swabs
in the diagnosis and management of chorioamnionitis. In fact,
the Royal College of Obstetricians and Gynaecologists rec-
ommends that, in the management of PPROM, women
should be observed for signs of clinical chorioamnionitis, and
weekly high vaginal swabs should not be performed [35].
Several laboratory assessments have been investigated for
their potential usefulness in the early prediction and diagno-
sis of chorioamnionitis. A low vaginal ‘pool’ amniotic ﬂuid
glucose measurement (<5 mg/dL) was shown to be a predic-
tive but not sensitive marker for infection in women with
PPROM [38]. Similarly, several potential biomarkers of early
chorioamnionitis have been identiﬁed, including interleukin-6,
interleukin-8, C-reactive protein, matrix metalloproteinase-8,
ferritin and placental alkaline phosphatase [4]. The reliability
(a) (b)
FIG. 1. Photomicrographs of a normal
chorionic plate (a) and a chorionic plate
with severe acute chorioamnionitis (b).
Note the extensive neutrophil inﬁltra-
tion throughout the entire chorionic
plate in the placenta affected by acute
chorioamnionitis. Original magniﬁcation
·250. Photomicrographs courtesy of Dr
Sarah Keating.
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and effectiveness of these biomarkers have not been
conﬁrmed in clinical trials. Other biomarkers, such as fetal
ﬁbronectin, relaxin, thrombin–antithrombin complex and
salivary proteases, have also been investigated, but appear to
be more speciﬁc in the prediction of PTB or PPROM than of
chorioamnionitis [4].
As chorioamnionitis and intrauterine infection remain
strong predictive markers of impaired cognitive and neuro-
developmental outcome [39,40], much research has revolved
around the use of proteomic technology to identify biomar-
kers that may be used in the accurate diagnosis and predic-
tion of neonatal outcomes in women with intrauterine
inﬂammation [41–43]. Protein markers, including neutrophil
defensin-1, defensin-2, calgranulin-A and calgranulin-C, have
been associated with inﬂammation in the amniotic ﬂuid and
placenta. These have been correlated with stages of histolog-
ical chorioamnionitis, grades of choriodeciduitis and amnioni-
tis [44]. Furthermore, they have been associated with an
increased risk of neonatal sepsis [45]. Currently, proteomics
is a research technique, and is not used in clinical practice;
however, future development of this technology and other
diagnostic tests may prove to be important in determining
patients at high risk of adverse outcomes from suspected
intra-amniotic infection and chorioamnionitis.
In summary, owing to a lack of speciﬁc and sensitive tests
that are safe for both mother and fetus, the diagnosis of cho-
rioamnionitis is based predominantly on clinical signs and
symptoms. Although amniocentesis is the most sensitive tool
for culturing pathogens, its routine use is not recommended.
The use of blood cultures, placental swabs and high vaginal
swabs has yet to be shown to alter management and
improve maternal and fetal outcome.
Treatment
Treatment of acute chorioamnionitis includes antimicrobial
agents, antipyretics, expedition of delivery and management
of additional symptoms. Despite the fact that chorioamnioni-
tis is common, there is limited evidence to support one spe-
ciﬁc antibiotic regimen over another. The vast majority of
studies, including several randomized controlled trials
(RCTs), have used intravenous ampicillin 2 g every 6 h for
coverage of Gram-positive organisms, intravenous gentamicin
1.5 mg/kg every 8 h for coverage of Gram-negative organ-
isms, and intravenous clindamycin 900 mg every 8 h for addi-
tional coverage of anaerobes in the event of a caesarean
section [37,46–48]. There is very little variation from this
regimen in the literature with regard to intrapartum treat-
ment. There is also little discussion of alternative drugs in
the case of allergy, with one study using intravenous clinda-
mycin 900 mg every 8 h as an alternative to ampicillin [37].
Metronidazole has also been reported as an alternative to
clindamycin [46], and vancomycin or erythromycin as addi-
tional alternatives if the patient is allergic to penicillin [32];
however, there have been no RCTs to date comparing
alternative regimens with the standard regimen of ampicillin
and gentamicin.
The existing trials of antibiotic treatment have focused on
variations in dosing and timing of drug administration and
alterations to the spectrum of coverage. One RCT found a
lower risk of postpartum endometritis in women treated
with clindamycin in addition to ampicillin and gentamicin who
had a vaginal delivery. There were no differences in women
delivering by caesarean section [49]. A subsequent study
showed a reduction in the risk of postpartum endometritis
with additional anaerobic coverage at caesarean section
(8.8% in the ampicillin–sulbactam group vs. 35% in the ampi-
cillin-alone group) [50]. Thus, the recommendation was
made to add anaerobic coverage for women with chorio-
amnionitis who are undergoing delivery by caesarean section
[46].
In previous debates about the timing of treatment for cho-
rioamnionitis, it had been argued that antibiotic treatment in-
trapartum may affect neonatal cultures, mask early neonatal
sepsis and thus delay treatment, leading to poorer neonatal
outcomes. This issue was addressed in the late 1980s, in a
prospective cohort study and an RCT comparing intrapartum
and immediate postpartum treatment with ampicillin and
gentamicin. Although both studies were small, with 257
women in the cohort study and only 48 enrolled in the
RCT, women who received intrapartum treatment had
shorter hospital stays and improved neonatal outcomes, sug-
gesting that intrapartum treatment is superior [47,51].
Despite the paucity of evidence, the current standard of
practice is to initiate treatment with antibiotics promptly
once the diagnosis of chorioamnionitis has been made.
Although delivery should be expedited, caesarean section is
still reserved for the usual obstetric indications [52].
Several trials have further investigated the beneﬁts of
extending treatment of intrapartum chorioamnionitis into
the postpartum period beyond a single postpartum dose.
One RCT randomized women delivering vaginally with a
diagnosis of intrapartum chorioamnionitis to a single postpar-
tum dose of cefotetan or continued cefotetan for a minimum
of 48 h. No differences were shown between the groups in
infectious morbidity, although the study was not powered to
look at rare outcomes [53]. A study of single vs. multiple
postpartum doses of clindamycin and gentamicin in women
randomized after caesarean section also revealed no differ-
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ences in infectious morbidity. In particular, there was no dif-
ference in the rate of endometritis, the primary outcome.
However, the predetermined sample size was not reached,
and the study may thus have been underpowered to show
a difference if one exists [54]. The largest randomized
trial to investigate short-course vs. longer-course antibiotics
postpartum after treated intrapartum chorioamnionitis was
published in 2003, and enrolled 292 women. Participants
were randomized to receive one additional scheduled dose
of ampicillin and gentamicin postpartum or to the control
group, who continued to receive ampicillin and gentamicin
until they were afebrile and asymptomatic for 24 h post-
partum. There were no signiﬁcant differences in the primary
outcome of treatment failure, and there were signiﬁcantly
shorter hospital stays in the study group [48], suggesting that
prolonged antibiotic therapy postpartum does not provide
additional beneﬁt beyond a single dose and leads to
increased costs.
More recently, trials of treatment of chorioamnionitis
have shifted towards testing the efﬁciency and safety
of once-daily dosing of gentamicin. Gentamicin is a com-
monly used aminoglycoside in pregnancy for the treatment
of Gram-negative bacteria, although there is reluctance by
some practitioners to use it, given the known side effects of
renal toxicity and ototoxicity. It is well established that
once-daily dosing has several advantages over multiple daily
doses, with higher peak serum levels leading to increased
efﬁcacy of bacterial killing, and prolonged lower trough levels
having a lower risk of toxicity [55]. Two recent randomized
trials have studied daily vs. divided dosing of gentamicin for
treatment of chorioamnionitis, and have found no differences
in any adverse maternal or neonatal outcomes, although both
studies were underpowered to detect small differences in
neonatal sepsis or permanent infant hearing loss [56,57]. Fur-
ther studies regarding these rare but important outcomes
are required before a recommendation can be made to
switch to once-daily dosing in labour.
Additional treatments in the management of acute chorio-
amnionitis include the antipyretic acetaminophen. A study of
fetal acid–base balance showed signiﬁcant improvements in
intrapartum fetal heart rate monitoring as well as in bicar-
bonate and base excess values (based on scalp gases and
cord gases) following treatment of intrapartum fever with
acetaminophen [58]. Finally, although there has been previ-
ous concern about the use of regional analgesia in women
with intrapartum fever, there does not seem to be any evi-
dence of increased risk of harm (i.e. epidural abscess forma-
tion or meningitis) in women with chorioamnionitis receiving
regional analgesia, even in those with no prior antibiotic
administration [59,60].
Prevention
Strategies to prevent chorioamnionitis and subsequent
adverse neonatal outcomes have focused on the identiﬁca-
tion and treatment of risk factors. One of the main risk
factors for chorioamnionitis is PPROM, and there has been
signiﬁcant debate in the literature about whether antibiotic
treatment of patients with PPROM will subsequently pre-
vent chorioamnionitis and thus adverse neonatal outcomes.
One of the largest trials to look at broad-spectrum antibi-
otic coverage for PPROM was the ORACLE I trial. This
study did not have chorioamnionitis as a primary or sec-
ondary outcome; however, in women treated with erythro-
mycin alone, neonatal outcome was improved, with
prolonged rupture to delivery intervals, a decrease in the
number of positive blood cultures and a trend to an
improved neonatal composite score [61]. A recent Cochrane
meta-analysis included several trials of antibiotic use in
PPROM, and included chorioamnionitis as an outcome mea-
sure [62]. This meta-analysis revealed a signiﬁcant reduction
in the risk of chorioamnionitis with any antibiotic treatment
(relative risk 0.66, 95% CI 0.46–0.96). There were also
reductions in markers of neonatal morbidity, including neo-
natal infection, use of surfactant, oxygen therapy and an
abnormal cerebral ultrasound ﬁnding prior to discharge
[62]. Unfortunately, the fact that trials with different antibi-
otic regimens were all grouped together provides no guid-
ance for the practitioner with respect to selecting a drug
for prophylactic treatment.
One of the most common organisms isolated from both
the lower genital tract and from placentas of women deliver-
ing prematurely is U. urealyticum. There is evidence that this
bacterium is associated with PTB; however, the effectiveness
of treatment with antibiotics is not clear. Evidence from a
randomized trial suggests that treatment of U. urealyticum
infection with erythromycin does not decrease vertical trans-
mission, but it may prolong latency and decrease the risk of
histological chorioamnionitis [63]. A further clinical study
speciﬁcally powered to investigate the impact of treatment
of U. urealyticum infection on the prevention of chorioamnio-
nitis is warranted.
In the setting of intact membranes, the use of antibiotics,
both as a preventive measure for PTB and as a treatment for
subclinical/clinical vaginal infections, has been investigated.
Clinical trials have shown no beneﬁt of antibiotic treatment
for the prevention of PTB in the absence of cultured infec-
tion [64], or even with documented microbial invasion of the
amniotic cavity [65]. Another study of 2433 African women
found no differences in the risk of chorioamnionitis in
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women treated with antibiotics prophylactically, although
rates of Trichomonas and bacterial vaginosis did decline with
treatment [66]. Although several international associations
recommend treatment of bacterial vaginosis in pregnancy in
women who are high risk, it is not clear that treatment itself
reduces the risk of preterm labour through a reduction in
intra-amniotic infection [67,68].
The use of vaginal irrigation and intra-amniotic infusion
has also been studied for the prevention of chorioamnionitis,
with varying results. Vaginal irrigation with chlorhexidine did
not have any adverse effects, but was unsuccessful in reduc-
ing the risk of chorioamnionitis or endometritis in treated
women [69]. Two small trials from the mid-1990s to late
1990s looked at amnio-infusion to reduce the risk of chorio-
amnionitis, and both showed a degree of beneﬁt, although
these studies were never followed with larger, appropriately
powered, prospective RCTs [70,71].
Finally, there has also been a suggestion that antibiotic
treatment of patients with meconium-stained amniotic ﬂuid
reduces intra-amniotic infection, although with no beneﬁt in
terms of lower rates of neonatal sepsis [72]. Currently,
there is no clear evidence for or against this treatment.
Summary
Chorioamnionitis is a common obstetric problem, and if
untreated can lead to signiﬁcant maternal and neonatal mor-
bidity and mortality. Chorioamnionitis is diagnosed on the
basis of either clinical and/or histological ﬁndings. Once it
has been identiﬁed, prompt treatment is recommended with
broad-spectrum antibiotics, antipyretics, supportive care and
expedition of delivery. Further research is needed to charac-
terize the microbial communities found in the female genital
tract, both in normal pregnancy and in pathological condi-
tions such as chorioamnionitis. Similarly, further research is
needed to identify screening and predictive investigations,
with appropriate prospective validation of any potential test
prior to its widespread use. Ongoing research on novel bio-
markers may help to provide further information on the aeti-
ology, causative pathways and potential interventions to help
in the treatment and prevention of chorioamnionitis.
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